» Articles » PMID: 36649274

Machine Learning with Textural Analysis of Longitudinal Multiparametric MRI and Molecular Subtypes Accurately Predicts Pathologic Complete Response in Patients with Invasive Breast Cancer

Overview
Journal PLoS One
Date 2023 Jan 17
PMID 36649274
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To predict pathological complete response (pCR) after neoadjuvant chemotherapy using extreme gradient boosting (XGBoost) with MRI and non-imaging data at multiple treatment timepoints.

Material And Methods: This retrospective study included breast cancer patients (n = 117) who underwent neoadjuvant chemotherapy. Data types used included tumor ADC values, diffusion-weighted and dynamic-contrast-enhanced MRI at three treatment timepoints, and patient demographics and tumor data. GLCM textural analysis was performed on MRI data. An extreme gradient boosting machine learning algorithm was used to predict pCR. Prediction performance was evaluated using the area under the curve (AUC) of the receiver operating curve along with precision and recall.

Results: Prediction using texture features of DWI and DCE images at multiple treatment time points (AUC = 0.871; 95% CI: (0.768, 0.974; p<0.001) and (AUC = 0.903 95% CI: 0.854, 0.952; p<0.001) respectively), outperformed that using mean tumor ADC (AUC = 0.850 (95% CI: 0.764, 0.936; p<0.001)). The AUC using all MRI data was 0.933 (95% CI: 0.836, 1.03; p<0.001). The AUC using non-MRI data was 0.919 (95% CI: 0.848, 0.99; p<0.001). The highest AUC of 0.951 (95% CI: 0.909, 0.993; p<0.001) was achieved with all MRI and all non-MRI data at all time points as inputs.

Conclusion: Using XGBoost on extracted GLCM features and non-imaging data accurately predicts pCR. This early prediction of response can minimize exposure to toxic chemotherapy, allowing regimen modification mid-treatment and ultimately achieving better outcomes.

Citing Articles

Advancing Precision Oncology Through Modeling of Longitudinal and Multimodal Data.

Zhuang L, Park S, Skates S, Prosper A, Aberle D, Hsu W ArXiv. 2025; .

PMID: 39990791 PMC: 11844620.


Advancing personalized oncology: a systematic review on the integration of artificial intelligence in monitoring neoadjuvant treatment for breast cancer patients.

Hachache R, Yahyaouy A, Riffi J, Tairi H, Abibou S, Adoui M BMC Cancer. 2024; 24(1):1300.

PMID: 39434042 PMC: 11495077. DOI: 10.1186/s12885-024-13049-0.


Machine learning prediction of pathological complete response and overall survival of breast cancer patients in an underserved inner-city population.

DellAquila K, Vadlamani A, Maldjian T, Fineberg S, Eligulashvili A, Chung J Breast Cancer Res. 2024; 26(1):7.

PMID: 38200586 PMC: 10782738. DOI: 10.1186/s13058-023-01762-w.


Prediction of therapy response of breast cancer patients with machine learning based on clinical data and imaging data derived from breast [F]FDG-PET/MRI.

Jannusch K, Dietzel F, Bruckmann N, Morawitz J, Boschheidgen M, Minko P Eur J Nucl Med Mol Imaging. 2023; 51(5):1451-1461.

PMID: 38133687 PMC: 10957677. DOI: 10.1007/s00259-023-06513-9.


Exploring Neoadjuvant Chemotherapy, Predictive Models, Radiomic, and Pathological Markers in Breast Cancer: A Comprehensive Review.

Elsayed B, Alksas A, Shehata M, Mahmoud A, Zaky M, Alghandour R Cancers (Basel). 2023; 15(21).

PMID: 37958461 PMC: 10648987. DOI: 10.3390/cancers15215288.


References
1.
Mani S, Chen Y, Li X, Arlinghaus L, Chakravarthy A, Abramson V . Machine learning for predicting the response of breast cancer to neoadjuvant chemotherapy. J Am Med Inform Assoc. 2013; 20(4):688-95. PMC: 3721158. DOI: 10.1136/amiajnl-2012-001332. View

2.
Partridge S, Zhang Z, Newitt D, Gibbs J, Chenevert T, Rosen M . Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial. Radiology. 2018; 289(3):618-627. PMC: 6283325. DOI: 10.1148/radiol.2018180273. View

3.
Li X, Arlinghaus L, Ayers G, Chakravarthy A, Abramson R, Abramson V . DCE-MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: pilot study findings. Magn Reson Med. 2013; 71(4):1592-602. PMC: 3742614. DOI: 10.1002/mrm.24782. View

4.
Dammu H, Ren T, Duong T . Deep learning prediction of pathological complete response, residual cancer burden, and progression-free survival in breast cancer patients. PLoS One. 2023; 18(1):e0280148. PMC: 9821469. DOI: 10.1371/journal.pone.0280148. View

5.
Suo S, Yin Y, Geng X, Zhang D, Hua J, Cheng F . Diffusion-weighted MRI for predicting pathologic response to neoadjuvant chemotherapy in breast cancer: evaluation with mono-, bi-, and stretched-exponential models. J Transl Med. 2021; 19(1):236. PMC: 8173748. DOI: 10.1186/s12967-021-02886-3. View